Clinical Trials Browser

Leukemia, Lymphocytic, Chronic, B-Cell × SNX-5422 × Clear all

NCT02973399 2019-02-22

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell